Related Experiment Video
Updated: May 24, 2026

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
Hyperhidrosis related to nevirapine therapy
A Belda1, J Borrás-Blasco, D Rosique-Robles
1Internal Medicine Service, Hospital de Sagunto, Valencia, Spain.
Nevirapine, an antiretroviral therapy (ART) drug, can cause severe hyperhidrosis (excessive sweating) and asthenia. Switching to efavirenz resolved these adverse effects, suggesting nevirapine as the probable cause.
Area of Science:
- Pharmacology
- Clinical Medicine
- Adverse Drug Reactions
Background:
- Antiretroviral therapy (ART) is crucial for managing HIV/AIDS.
- Non-nucleoside reverse transcriptase inhibitors (NNRTIs) like nevirapine are common ART components.
- Adverse drug reactions can impact patient adherence and quality of life.
Observation:
- A 70-year-old male on ART (tenofovir, lamivudine, nevirapine) developed severe hyperhidrosis and asthenia.
- Symptoms emerged shortly after initiating nevirapine.
- A strong temporal relationship existed between nevirapine use and symptom onset.
Findings:
- Nevirapine was identified as the probable causative agent for hyperhidrosis and asthenia.
- Discontinuation of nevirapine and substitution with efavirenz led to rapid symptom resolution (2-3 days).
- No relapse occurred with the new regimen, confirming causality.
Implications:
- Clinicians should consider nevirapine as a potential cause of unexplained hyperhidrosis in patients on ART.
- Discontinuation or substitution of nevirapine may be necessary to manage this adverse drug reaction.
- Further research is warranted to understand the incidence and mechanisms of nevirapine-induced hyperhidrosis.
Related Concept Videos
Increased Body Temperature
Nephrotic Syndrome III : Nursing Management
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
Phenothiazines, such as prochlorperazine...
Nephrotic Syndrome I : Introduction
Drug toxicity: Idiosyncratic Reactions
Therapeutic Drug Monitoring: Affecting Factors
